source
- NodThera rebrands as Rezera and targets Phase 3 trial in 2027NodThera, a biotech focused on the NLRP3 inflammatory pathway for about ten years, announced a strategic shift. The company said it will rebrand itself as Rezera and is preparing to launch a pivot…
- Evommune's MRGPRX2 antagonist fails second Phase 2b trial in atopic dermatitisEvommune reported that its experimental small-molecule antagonist of the MRGPRX2 receptor did not meet its primary endpoints in a Phase 2b study in patients with atopic dermatitis. The study, cond…